ALK and neuroblastoma: Based on the unusual binding properties of this inhibitor in the ATP binding pocket we decided to explore the therapeutic potential of repotrectinib in the context of full length ALK in a neuroblastoma setting where the gain-of-function mutations occur mostly around the α-C-helix and activation loop.